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Abstract
Akt is a serine/threonine kinase that transduces sur-
vival signals from survival/growth factors. Deregula-
tion and signal imbalance in cancer cells make them
prone to apoptosis. Upregulation or activation of Akt
to aid the survival of cancer cells is a common theme
in human malignancies. We have developed small-
molecule Akt inhibitors that are potent and specific.
These Akt inhibitors can inhibit Akt activity and block
phosphorylation by Akt on multiple downstream tar-
gets in cells. Synergy in apoptosis induction was ob-
served when Akt inhibitors were combined with
doxorubicin or camptothecin. Akt inhibitor–induced
enhancement of topoisomerase inhibitor cytotoxicity
was also evident in long-term cell survival assay. Syn-
ergy with paclitaxel in apoptosis induction was evident
in cells pretreated with paclitaxel, and enhancement of
tumor delay by paclitaxel was demonstrated through
cotreatment with Akt inhibitor Compound A (A-443654).
Combination with other classes of chemotherapeutic
agents did not yield any enhancement of cytotoxicity.
These findings provide important guidance in selecting
appropriate classes of chemotherapeutic agents for
combination with Akt inhibitors in cancer treatment.
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Introduction
Akt is a serine–threonine kinase activated by growth fac-
tors or survival factors through phosphatidyl inositol 3V kinase
(PI3K)–3-phosphoinositide–dependent kinase 1 to promote
cell growth and survival [1–3]. PTEN (phosphatase and
tensin homolog deleted in chromosome 10), a lipid phospha-
tase, reverts the phosphorylation of phosphoinositol-3,4,5-
triphosphate by PI3K and thus prevents Akt activation [2,4,5].
Akt promotes cell survival through phosphorylation and in-
activation of key components in apoptotic cascade, such as
Bad [6–8], caspase 9 [9], and ASK1 [10]. Akt also down-
regulates the expression of proapoptotic proteins, such as
Fas ligand, through the phosphorylation and inactivation of
forkhead transcription factors FOXO3 (FKHRL1) and FOXO4
(AFX) [11–13]. Another important downstream target of Akt is
glycogen synthase kinase 3 (GSK3). Inactivation of GSK3 on
phosphorylation by Akt leads to protection from apoptosis [2].
Furthermore, Akt has been shown to enhance the function of
transcription factor NFnB, thereby upregulating the expression
of antiapoptotic proteins, such as cIAP1 and cIAP2. Recently,
Akt was also reported to phosphorylate and stabilize PED/
PEA-15, an antiapoptotic protein [14].
Akt is either overexpressed or activated in a variety of
human cancers, including lung, breast, ovarian, gastric, and
pancreatic carcinomas [15–23]. Increased Akt expression also
correlates with disease progression [17,24]. Furthermore, PTEN
mutations that result in increased Akt activity have been reported
in a wide variety of malignancies, including breast cancer,
prostate cancer, melanoma, glioblastomamultiforme, and endo-
metrial cancer [25–36].
Akt activation and overexpression are often associated with
resistance to chemotherapy or radiotherapy [37–40]. Reversal
of drug resistance has been demonstrated in both cell-based
studies and animal models by PI3K inhibitors and PTEN over-
expression in PTEN-null cells [41–47]. Dominant-negative mu-
tants of Akt were also shown to enhance cytotoxicity by
chemotherapeutic agents [48], suggesting an important role
of Akt in drug resistance. Furthermore, inhibition of receptor
tyrosine kinases, such as epidermal growth factor receptor,
sensitizes cells to chemotherapy or radiotherapy through down-
regulation of the PI3K–Akt pathway [38,49–53]. Thus, clinically
suitable small-molecule inhibitors of Akt have great potential in
cancer treatment. In addition, identifying suitable classes of che-
motherapeutic agents that could be sensitized by Akt inhibition
is highly desired to guide the clinical application of Akt inhibitors.
Abbreviations: PI3K, phosphatidyl inositol 3V kinase; PTEN, phosphatase and tensin homolog
deleted in chromosome 10; GSK3, glycogen synthase kinase 3
Address all correspondence to: Yan Luo, MD, PhD, Department R47S, Cancer Research,
Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064. E-mail: yan.luo@abbott.com
1Yan Shi and Xuesong Liu contributed equally to this work.
Received 11 May 2005; Revised 19 August 2005; Accepted 19 August 2005.
Copyright D 2005 Neoplasia Press, Inc. All rights reserved 1522-8002/05/$25.00
DOI 10.1593/neo.05355
Neoplasia . Vol. 7, No. 11, November 2005, pp. 992 –1000 992
www.neoplasia.com
RESEARCH ARTICLE
We have developed specific small-molecule inhibitors
against Akt [54]. In this study, we have shown that Akt
activity was modulated by various classes of chemothera-
peutic agents. Akt inhibitors demonstrated synergy only with
topoisomerase I inhibitors, topoisomerase II inhibitors, and
paclitaxel in apoptosis induction in human cancer cell lines.
Combination with other classes of chemotherapeutic agents
did not enhance apoptosis induction. Akt inhibitors were
also shown to enhance tumor growth delay by paclitaxel in
a PC-3 xenograft model. Thus, we identified optimal classes
of chemotherapeutic agents for combination with Akt inhibi-
tors in cancer treatment.
Materials and Methods
Cell Lines and Materials
MiaPaCa, H460, 786-0, and MDA-MB468 cells were pur-
chased from the American Type Culture Collection (ATCC;
Manassas, VA). Cells were cultured according to instruc-
tions from the ATCC. Akt inhibitors were synthesized
as described [54].
Western Blot Analysis
Cells were harvested and lysed in an insect cell lysis
buffer (10 mM Tris, pH 7.5, 130 mM NaCl, 1% Triton X-100,
10 mM NaF, 10 mM NaPi, and 10 mM NaPPi) supplemented
with 50 protease inhibitor cocktail (BD Pharmingen, Bed-
ford, MA) and 1 mM microcystin LR (Sigma Chemical Co.,
St. Louis, MO). Fifty micrograms of total protein was loaded
and resolved under reducing conditions on a 4% to 12% Tris-
glycine gel (Invitrogen, Carlsbad, CA). Western blot analysis
was performed with antibodies, as indicated. All antibodies
were purchased from Cell Signaling, Inc. (Beverly, MA).
Caspase Assay
The assay was carried out as described [55]. Caspase
activity is presented as units of fluorescence change per hour
(dFU/hr). Each data point is the average of three values.
Error bars represent standard deviation.
Soft Agar Assay
One milliliter of a 0.5% agar was first placed in each well
of six-well plates to form the bottom layer of the agar. Then
2ml of a 0.3% top agar containing 1 104 cells and complete
medium was layered on top of the solidified bottom layer
of the agar. After 2 weeks in culture, colonies were stained
with p-iodonitrotetrazolium violet, and the numbers and sizes
of colonies were quantified using Image-Pro Plus (Media
Cybernetics, Silver Spring, MD). Each value is the average
of two values. Error bars represent the range of values.
Tumor Efficacy Study
Animal studies were conducted following the guidelines of
the Institutional Animal Care and Use Committee. Immuno-
compromised male scid mice (C.B-17-Prkdcscid ), at 6 to
8 weeks of age, were obtained from Charles River Labora-
tories (Wilmington, MA). PC-3 cells were obtained from the
ATCC. Two million PC-3 cells in 50% Matrigel (BD Bio-
sciences, Bedford, MA) were inoculated subcutaneously
into the flank. Sixteen days after inoculation, tumors were
assigned to treatment groups, with an average size of
185 mm3 per group, and therapy was started on the same
day (n = 10 mice per group). Tumor size was evaluated by
twice-weekly measurements with digital calipers. Tumor
volume was estimated using the formula: V = LW 2. Com-
pound A was administered subcutaneously in a vehicle of
0.2% HPMC. Paclitaxel was obtained from Bristol-Myers
Squibb (Princeton, NJ) and administered in three doses at
4-day intervals, according to the manufacturer’s instructions.
Results
Properties of Akt Inhibitors
We developed small-molecule inhibitors against Akt1
[54]. The structure, potency, and selectivity of three Akt
Figure 1. Potency and selectivity of Akt inhibitors. The potency and selectivity of Akt inhibitors were measured as described [54]. Each value is the average of
several determinations. Compound A is a very selective inhibitor; Compound B is the enantiomer of Compound A; Compound C is another selective Akt inhibitor.
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inhibitors are shown in Figure 1. Compound A, which is a
very selective inhibitor, inhibits Akt1, with a Ki = 160 pM, and
it inhibits Akt2 and Akt3 with similar potency [54]. We have
tested over 40 different kinases that represent different
family members of the human kinome; the kinases that were
inhibited significantly by Akt inhibitors are listed in Figure 1.
PKA is the least selective kinase for Compound A, and the
selectivity between Akt1 and PKA is 39-fold. Compound B is
the enantiomer of Compound A. Its potency against Akt1 is
177-fold lower than that of Compound A, whereas the po-
tencies against other kinases were very similar to that of
Compound A [54]. Therefore, the pair of these two com-
pounds provides an ideal tool to study Akt functions in cells.
In addition, another selective Akt inhibitor, Compound C, in-
hibits Akt, with a Ki = 0.7 nM (Figure 1).
Akt inhibition by these compounds was measured in cells.
The phosphorylation of multiple Akt downstream targets
is shown in Figure 2. Consistent with Akt potencies in test
tubes, Compound A inhibited the phosphorylation of these
Akt substrates with an EC50 = 0.3 mM, whereas EC50 = 3 to
10 mM for Compound B. Compound C inhibited Akt in cells
with an EC50 = 1 mM (Figure 2).
Synergy between Akt Inhibitors and Certain Classes of
Chemotherapeutic Agents in Killing Human Cancer Cells
The ability of Akt inhibitors to potentiate apoptosis induc-
tion in human cancer cell lines was assessed in combina-
tion with various classes of chemotherapeutic agents. H460
cells were pretreated with Akt inhibitors, followed by cotreat-
ment with camptothecin, doxorubicin, cisplatin, paclitaxel,
5-fluorouracil, and gemcitabine. Caspase activation was com-
pared between cells on single treatment and cells on com-
bination treatment. Caspase activation was minimal in cells
treated with either Akt inhibitors alone or chemotherapeu-
tic agents alone within the concentration range tested. Sig-
nificant synergy was detected between Compound A and
certain classes of chemotherapeutic agents, such as camp-
tothecin and doxorubicin, whereas no synergy was observed
with other classes of chemotherapeutic agents (Figure 3).
Nearly all the cells underwent apoptosis with 1 mM Com-
pound A and the highest concentration of doxorubicin or
camptothecin (Figure 3B). Within the same concentration
range wherein synergy was demonstrated with cytotoxic
agents in apoptosis induction, Compound A inhibited the
phosphorylation of GSK3 and tuberous sclerosis 2 by Akt
in a dose-dependent manner (Figures 2 and 3). All of these
are important Akt targets that are involved in apoptosis in-
duction or cell growth/survival. Combination with paclitaxel in
the same regimen did not exhibit any synergy between the
two agents (data not shown). However, when the cells were
pretreated with paclitaxel for 24 hours before the addition of
Compound A, synergy was detected (Figure 3D). Treatment
with another Akt inhibitor, Compound C, displayed a simi-
lar potentiation profile (Figure 3, A, C, and D).
We evaluated the enantiomer of Compound A (Com-
pound B) in these combination experiments in the same
concentration range. At these concentrations, Compound B
did not inhibit Akt (Figure 1B). There was no evidence of
synergy in caspase activation detected in combination with
any chemotherapeutic agent (Figure 3). Therefore, synergy
in apoptosis induction was demonstrated between Akt in-
hibitors and camptothecin, doxorubicin, and paclitaxel. The
same set of combination treatments was also performed in
the human colon carcinoma cell line DLD-1, and similar re-
sults were observed (data not shown). In contrast, no syn-
ergy was observed in any combination treatment in normal
human fibroblasts (Figure 3F ).
We examined Akt activation by different classes of che-
motherapeutic agents. H460 lung carcinoma cells were
treated with various chemotherapeutic agents for different
lengths of time, and phosphorylation activation at serine 473
was used as an indicator of Akt activation [3]. Almost all
classes of chemotherapeutic agents modulated Akt activity
during the first few hours of treatment. Initial suppression
of Akt was observed during the first hour of treatment. How-
ever, Akt phosphorylation returned to the basal level after
Figure 2. Inhibition of cellular Akt activity by Akt inhibitors. MDA-MB468 cells were treated with Akt inhibitors for 2 hours. The total cell lysate was extracted and
subjected to Western blot analysis. A corresponds to Compound A in Figure 1, while B corresponds to Compound B, and C corresponds to Compound C.
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3 hours of treatment (Figure 4A). One can hypothesize
that, immediately after DNA damage, cells may respond by
decreasing signaling through mitogenic pathways, such as
the PI3K–Akt pathway, to stop cell cycle progression. Sub-
sequently, however, the cells struggle to survive during the
DNA repair process; thus, upregulation of Akt for its apoptosis-
protecting function may become critical for cell survival.
We also measured the levels of several antiapopto-
tic proteins in cells subjected to combination treatment.
The levels of Bcl2, BclXl, and XIAP did not change in any
combination treatment. However, although Mcl-1 levels were
reduced by Compound A itself, more dramatic reductions in
Mcl-1 levels were observed with the combination of Com
pound A and camptothecin, doxorubicin, paclitaxel, and cis-
platin (Figure 4). These may explain the synergy observed
in caspase activation, except in the case of combination
with cisplatin.
The impact of Akt inhibitors on cell survival after chemo-
therapy was investigated. We found that cells were more
sensitive to either chemotherapeutic agents (doxorubicin
and camptothecin) or Akt inhibitors alone in soft agar assay
(data not shown). This may be a result of a much lower cell
density at the beginning of drug treatments. Therefore, com-
bination treatment was carried out with lower concentrations
of both Akt inhibitors and chemotherapeutic agents. Both
Compound A and Compound C significantly enhanced cyto-
toxicity by doxorubicin or camptothecin in the long-term soft
agar assay (Figure 5).
Figure 3. Synergy between Akt inhibitors and certain classes of chemotherapeutic agents in apoptosis induction. (A, C, and E) H460 cells were treated with Akt
inhibitors for 17 hours, followed by cotreatment with different chemotherapeutic agents for an additional 7 hours. Caspase assay was performed. (B) H460 cells
were treated with 1 M Compound A for 17 hours, followed by cotreatment with either 3 M doxorubicin or 1 M camptothecin for an additional 24 hours. Cells were
stained with DAPI for DNA staining. The cells that contained nuclear condensation and fragmentation were scored as apoptotic cells. At least 700 cells were
counted in each sample. (D) H460 cells were pretreated with paclitaxel for 24 hours followed by cotreatment with Akt inhibitors for an additional 17 hours. Caspase
assay was performed. Representative data from several experiments are shown. (F) NHF cells were treated as in (C) and (E). Caspase assay was performed.
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Akt Inhibitor Sensitizes Tumors to Paclitaxel in the PC-3
Xenograft Model
To examine the ability of Akt inhibitors to potentiate the
activity of cytotoxic agents in vivo, we studied a PC-3
prostate xenograft model utilizing Compound A in com-
bination with paclitaxel as a test case. The treatment was
initiated on established flank tumors. Compound A was
efficacious at 7.5 mg/kg per day as monotherapy in a va-
riety of tumor models [54]. When given as monotherapy
at 2.5 mg/kg per day (from days 16 to 32), Compound A did
not yield any statistically significant efficacy. Similarly, pacli-
taxel given at half of the maximally tolerated dose of 15 mg/kg
per day (on days 16, 20, and 24) only generated modest,
transiently significant efficacy. However, the combination of
Compound A plus paclitaxel resulted in inhibition of tumor
growth that was significantly improved compared to pacli-
taxel monotherapy (P < .05), consistent with the results we
obtained in tissue-cultured cells (Figure 6). This result dem-
onstrates the ability of Akt inhibitors to sensitize tumors to
chemotherapy in vivo.
Discussion
The PI3K–Akt pathway plays a pivotal role in promoting
cell survival, and it has been implicated in drug resistance.
The inhibition of the pathway through either PI3K inhibitors
or PTEN expression has been demonstrated to sensitize
cancer cells to chemotherapy [39,41–44,46,47]. The role of
Akt in the pathway for drug resistance was also suggested
by demonstrating that Akt dominant-negative mutants sen-
sitize cells to drug treatment [48]. Recently, several in-
hibitors that prevent Akt activation have been reported to
induce cytotoxicity or to sensitize cancer cells to apop-
tosis [56–61]. To date, clinically relevant, pharmacologic
Figure 3. (continued)
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inhibition of Akt has not been examined in combination
therapy in vivo, and the best class of chemotherapy that
could be used in combination with Akt inhibitors has not
been systematically investigated.
In this study, we report very potent and selective Akt
inhibitors with Ki values as low as 160 pM. We have tested
these Akt inhibitors in combination with representative
classes of chemotherapeutic agents, and we have demon-
strated that Akt inhibition sensitizes tumor cells only to
certain chemotherapeutic agents, but not to others. Both
Compound A and Compound C inhibited Akt pharmacolog-
ically and sensitized tumor cells only to camptothecin, doxo-
rubicin, and paclitaxel (Figure 3). The enantiomeric isomer of
Compound A (Compound B) was 177-fold less active against
Akt, whereas it inhibited other kinases with similar potency.
Compound B did not enhance cytotoxicity to any of these
classes of chemotherapeutic agents, suggesting that Akt
inhibition underlies the mechanism of chemosensitization.
Some of these cytotoxic agents have been shown to be
sensitized by PTEN overexpression [41,42] and Akt inhibi-
tion [61]. In contrast, no synergy in apoptosis induction was
observed in the combination treatment with other classes of
chemotherapeutic agents (Figure 3). PI3K inhibitors were
shown to enhance the antitumor activity of gemcitabine
Figure 5. Akt inhibition enhances the cytotoxicity of chemotherapeutic agents. Cells were pretreated with Akt inhibitors together with chemotherapeutic agents for
48 hours. Soft agar assay was performed to assess long-term cell survival after treatment. Representative data from several experiments were shown.
Figure 6. Combination treatment of Compound A plus paclitaxel in the PC-3
xenograft flank tumor model. Sixteen days after inoculation, tumors were
size-matched to approximately 185 mm3, and therapy was initiated on the
same day. Tumor volume versus days after inoculation is plotted.
Figure 4. (A) Akt phosphorylation is modulated by chemotherapy. Cells were
treated with various chemotherapeutic agents and subjected to Western blot
analysis as indicated. (B) Antiapoptotic protein levels in cells subjected to
combination treatments. H460 cells were treated as in Figure 3, and lysates
were made and subjected to Western blot analysis as indicated.
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[47,62], although we did not observe any enhancement of
apoptosis induction when AKT inhibitors were combined
with gemcitabine. This may be due to an Akt-independent
activity of PI3K.
More importantly, we examined combination effects in the
PC-3 xenograft model. Codosing of Compound A with pac-
litaxel enhanced tumor growth delay compared to that by
paclitaxel alone, demonstrating the achievable benefits of
combination therapy with Akt inhibitors in vivo (Figure 6).
These findings have significant clinical value in guiding the
selection of chemotherapeutic agents for optimal combina-
tion therapy with Akt inhibitors.
References
[1] Datta K, Bellacosa A, Chan TO, and Tsichlis PN (1996). Akt is a direct
target of the phosphatidylinositol 3-kinase. Activation by growth factors,
v-src and v-Ha-ras, in Sf9 and mammalian cells. J Biol Chem 271 (48),
30835–30839.
[2] Datta SR, Brunet A, and Greenberg ME (1999). Cellular survival: a play
in three Akts. Genes Dev 13 (22), 2905–2927.
[3] Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese
CB, and Cohen P (1997). Characterization of a 3-phosphoinositide–
dependent protein kinase which phosphorylates and activates protein
kinase B alpha. Curr Biol 7 (4), 261–269.
[4] Maehama T and Dixon JE (1998). The tumor suppressor, PTEN/
MMAC1, dephosphorylates the lipid second messenger, phosphatidyli-
nositol 3,4,5-trisphosphate. J Biol Chem 273 (22), 13375–13378.
[5] Gu J, Tamura M, and Yamada KM (1998). Tumor suppressor PTEN
inhibits integrin- and growth factor –mediated mitogen-activated protein
(MAP) kinase signaling pathways. J Cell Biol 143 (5), 1375–1383.
[6] Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, and Greenberg
ME (1997). Akt phosphorylation of BAD couples survival signals to the
cell-intrinsic death machinery. Cell 91 (2), 231–241.
[7] del Peso L, Gonzalez-Garcia M, Page C, Herrera R, and Nunez G
(1997). Interleukin-3– induced phosphorylation of BAD through the pro-
tein kinase Akt. Science 278 (5338), 687–689.
[8] Blume-Jensen P, Janknecht R, and Hunter T (1998). The kit recep-
tor promotes cell survival via activation of PI 3-kinase and subse-
quent Akt-mediated phosphorylation of Bad on Ser136. Curr Biol 8
(13), 779–782.
[9] CardoneMH, Roy N, Stennicke HR, SalvesenGS, Franke TF, Stanbridge
E, Frisch S, and Reed JC (1998). Regulation of cell death protease
caspase-9 by phosphorylation [see comments]. Science 282 (5392),
1318–1321.
[10] Kim AH, Khursigara G, Sun X, Franke TF, and Chao MV (2001). Akt
phosphorylates and negatively regulates apoptosis signal – regulating
kinase 1. Mol Cell Biol 21 (3), 893–901.
[11] Brunet A, Park J, Tran H, Hu LS, Hemmings BA, and Greenberg ME
(2001). Protein kinase SGK mediates survival signals by phosphorylat-
ing the forkhead transcription factor FKHRL1 (FOXO3a). Mol Cell Biol
21 (3), 952–965.
[12] Kops GJ and Burgering BM (1999). Forkhead transcription factors:
new insights into protein kinase B (c-akt) signaling. J Mol Med 77 (9),
656–665.
[13] Kops GJ, de Ruiter ND, De Vries-Smits AM, Powell DR, Bos JL, and
Burgering BM (1999). Direct control of the Forkhead transcription factor
AFX by protein kinase B. Nature 398 (6728), 630–634.
[14] Trencia A, Perfetti A, Cassese A, Vigliotta G, Miele C, Oriente F,
Santopietro S, Giacco F, Condorelli G, Formisano P, et al. (2003).
Protein kinase B/Akt binds and phosphorylates PED/PEA-15, stabi-
lizing its antiapoptotic action. Mol Cell Biol 23 (13), 4511–4521.
[15] Staal SP (1987). Molecular cloning of the akt oncogene and its human
homologues AKT1 and AKT2: amplification of AKT1 in a primary human
gastric adenocarcinoma. Proc Natl Acad Sci USA 84 (14), 5034–5037.
[16] Moore SM, Rintoul RC, Walker TR, Chilvers ER, Haslett C, and
Sethi T (1998). The presence of a constitutively active phosphoino-
sitide 3-kinase in small cell lung cancer cells mediates anchorage-
independent proliferation via a protein kinase B and p70s6k-dependent
pathway. Cancer Res 58 (22), 5239–5247.
[17] Bellacosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA,
Wan M, Dubeau L, Scambia G, Masciullo V, et al. (1995). Molecular
alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int
J Cancer 64 (4), 280–285.
[18] Dufourny B, Alblas J, van Teeffelen HA, van Schaik FM, van der Burg
B, Steenbergh PH, and Sussenbach JS (1997). Mitogenic signaling of
insulin-like growth factor I in MCF-7 human breast cancer cells requires
phosphatidylinositol 3-kinase and is independent of mitogen-activated
protein kinase. J Biol Chem 272 (49), 31163–31171.
[19] Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, Ma XL, Shelley SA,
Jove R, Tsichlis PN, Nicosia SV, et al. (2001). AKT1/PKB alpha kinase
is frequently elevated in human cancers and its constitutive activation is
required for oncogenic transformation in NIH3T3 cells. Am J Pathol 159
(2), 431–437.
[20] Thompson FH, NelsonMA, Trent JM, Guan XY, Liu Y, Yang JM, Emerson
J, Adair L, Wymer J, Balfour C, et al. (1996). Amplification of 19q13.1–
q13.2 sequences in ovarian cancer.G-band, FISH, andmolecular studies.
Cancer Genet Cytogenet 87 (1), 55–62.
[21] Yuan ZQ, Sun M, Feldman RI, Wang G, Ma X, Jiang C, Coppola D,
Nicosia SV, and Cheng JQ (2000). Frequent activation of AKT2 and
induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/
Akt pathway in human ovarian cancer. Oncogene 19 (19), 2324–2330.
[22] Miwa W, Yasuda J, Murakami Y, Yashima K, Sugano K, Sekine T, Kono
A, Egawa S, Yamaguchi K, Hayashizaki Y, et al. (1996). Isolation of
DNA sequences amplified at chromosome 19q13.1–q13.2 including
the AKT2 locus in human pancreatic cancer. Biochem Biophys Res
Commun 225 (3), 968–974.
[23] Ruggeri BA, Huang L, Wood M, Cheng JQ, and Testa JR (1998). Am-
plification and overexpression of the AKT2 oncogene in a subset of
human pancreatic ductal adenocarcinomas. Mol Carcinog 21 (2),
81–86.
[24] Nakatani K, Thompson DA, Barthel A, Sakaue H, Liu W, Weigel RJ, and
Roth RA (1999). Up-regulation of Akt3 in estrogen receptor–deficient
breast cancers and androgen-independent prostate cancer lines. J Biol
Chem 274 (31), 21528–21532.
[25] Di Cristofano A and Pandolfi PP (2000). The multiple roles of PTEN in
tumor suppression. Cell 100 (4), 387–390.
[26] Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH,
Langford LA, Baumgard ML, Hattier T, Davis T, et al. (1997). Identifi-
cation of a candidate tumour suppressor gene, MMAC1, at chromo-
some 10q23.3 that is mutated in multiple advanced cancers. Nat
Genet 15 (4), 356–362.
[27] Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis
C, Rodgers L, McCombie R, et al. (1997). PTEN, a putative protein
tyrosine phosphatase gene mutated in human brain, breast, and pros-
tate cancer [see comments]. Science 275 (5308), 1943–1947.
[28] Teng DH, Hu R, Lin H, Davis T, Iliev D, Frye C, Swedlund B, Hansen
KL, Vinson VL, Gumpper KL, et al. (1997). MMAC1/PTEN mutations
in primary tumor specimens and tumor cell lines. Cancer Res 57 (23),
5221–5225.
[29] Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG,
Jen J, Isaacs WB, Bova GS, and Sidransky D (1997). Frequent inacti-
vation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 57
(22), 4997–5000.
[30] Suzuki A, de la Pompa JL, Stambolic V, Elia AJ, Sasaki T, del Barco
Barrantes I, Ho A, Wakeham A, Itie A, Khoo W, et al. (1998). High
cancer susceptibility and embryonic lethality associated with muta-
tion of the PTEN tumor suppressor gene in mice. Curr Biol 8 (21),
1169–1178.
[31] Guldberg P, thor Straten P, Birck A, Ahrenkiel V, Kirkin AF, and Zeuthen
J (1997). Disruption of the MMAC1/PTEN gene by deletion or muta-
tion is a frequent event in malignant melanoma. Cancer Res 57 (17),
3660–3663.
[32] Liu W, James CD, Frederick L, Alderete BE, and Jenkins RB (1997).
PTEN/MMAC1 mutations and EGFR amplification in glioblastomas.
Cancer Res 57 (23), 5254–5257.
[33] Bostrom J, Cobbers JM, Wolter M, Tabatabai G, Weber RG, Lichter P,
Collins VP, and Reifenberger G (1998). Mutation of the PTEN (MMAC1)
tumor suppressor gene in a subset of glioblastomas but not in meningi-
omas with loss of chromosome arm 10q. Cancer Res 58 (1), 29–33.
[34] Wang SI, Puc J, Li J, Bruce JN, Cairns P, Sidransky D, and Parsons R
(1997). Somatic mutations of PTEN in glioblastoma multiforme. Cancer
Res 57 (19), 4183–4186.
[35] Rasheed BK, Stenzel TT, McLendon RE, Parsons R, Friedman AH,
Friedman HS, Bigner DD, and Bigner SH (1997). PTEN gene mutations
are seen in high-grade but not in low-grade gliomas. Cancer Res 57
(19), 4187–4190.
[36] Risinger JI, Hayes AK, Berchuck A, and Barrett JC (1997). PTEN/
Akt Inhibitors Sensitize Tumors to Chemotherapy Shi et al. 999
Neoplasia . Vol. 7, No. 11, 2005
MMAC1 mutations in endometrial cancers. Cancer Res 57 (21),
4736–4738.
[37] McKenna WG and Muschel Ruth J (2003). Targeting tumor cells by
enhancing radiation sensitivity. Genes Chromosomes Cancer 38 (4),
330–338.
[38] Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, Schmidt M, Mills
GB, Mendelsohn J, and Fan Z (2003). HER2/PI-3K/Akt activation
leads to a multidrug resistance in human breast adenocarcinoma
cells. Oncogene 22 (21), 3205–3212.
[39] West KA, Sianna Castillo S, and Dennis PA (2002). Activation of
the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist
Updates 5 (6), 234–248.
[40] Brognard J, Clark AS, Ni Y, and Dennis PA (2001). Akt/protein kinase B
is constitutively active in non–small cell lung cancer cells and promotes
cellular survival and resistance to chemotherapy and radiation. Cancer
Res 61 (10), 3986–3997.
[41] Saga Y, Mizukami H, Suzuki M, Kohno T, Urabe M, Ozawa K, and Sato
I (2002). Overexpression of PTEN increases sensitivity to SN-38, an
active metabolite of the topoisomerase I inhibitor irinotecan, in ovarian
cancer cells. Clin Cancer Res 8 (5), 1248–1252.
[42] Tanaka M, Koul D, Davies MA, Liebert M, Steck PA, and Grossman HB
(2000). MMAC1/PTEN inhibits cell growth and induces chemosensitiv-
ity to doxorubicin in human bladder cancer cells. Oncogene 19 (47),
5406–5412.
[43] Wick W, Furnari FB, Naumann U, Cavenee WK, and Weller M (1999).
PTEN gene transfer in human malignant glioma: sensitization to irradi-
ation and CD95L-induced apoptosis. Oncogene 18 (27), 3936–3943.
[44] Gupta Anjali K, Cerniglia George J,MickR, AhmedMonaS, Bakanauskas
Vincent J, Muschel Ruth J, and McKenna WG (2003). Radiation sensiti-
zation of human cancer cells in vivo by inhibiting the activity of PI3K using
LY294002. Int J Radiat Oncol Biol Phys 56 (3), 846–853.
[45] She Qing B, Solit D, Basso A, and Moasser Mark M (2003). Resistance
to gefitinib in PTEN-null HER-overexpressing tumor cells can be over-
come through restoration of PTEN function or pharmacologic modula-
tion of constitutive phosphatidylinositol 3V-kinase/Akt pathway signaling.
Clin Cancer Res 9 (12), 4340–4346.
[46] Hu L, Hofmann J, Lu Y, Mills GB, and Jaffe RB (2002). Inhibition of
phosphatidylinositol 3V-kinase increases efficacy of paclitaxel in in vitro
and in vivo ovarian cancer models. Cancer Res 62 (4), 1087–1092.
[47] Ng SS, Tsao MS, Nicklee T, and Hedley DW (2001). Wortmannin inhibits
pkb/akt phosphorylation and promotes gemcitabine antitumor activity
in orthotopic human pancreatic cancer xenografts in immunodeficient
mice. Clin Cancer Res 7 (10), 3269–3275.
[48] Clark AS, West K, Streicher S, and Dennis PA (2002). Constitutive and
inducible Akt activity promotes resistance to chemotherapy, trastuzumab,
or tamoxifen in breast cancer cells. Mol Cancer Ther 1 (9), 707–717.
[49] Lammering G, Hewit Theodore H, Valerie K, Contessa-Joseph N,
Amorino George P, Dent P, and Schmidt Ullrich Rupert K (2003).
EGFRvIII-mediated radioresistance through a strong cytoprotective re-
sponse. Oncogene 22 (36), 5545–5553.
[50] Cuello M, Ettenberg SA, Clark AS, Keane MM, Posner RH, Nau MM,
Dennis PA, and Lipkowitz S (2001). Down-regulation of the erbB-2
receptor by trastuzumab (herceptin) enhances tumor necrosis factor –
related apoptosis-inducing ligand-mediated apoptosis in breast and
ovarian cancer cell lines that overexpress erbB-2. Cancer Res 61
(12), 4892–4900.
[51] Tari AM, Lim SJ, Hung MC, Esteva FJ, and Lopez-Berestein G (2002).
Her2/neu induces all-trans retinoic acid (ATRA) resistance in breast
cancer cells. Oncogene 21 (34), 5224–5232.
[52] Munster PN, Marchion DC, Basso AD, and Rosen N (2002). Degrada-
tion of HER2 by ansamycins induces growth arrest and apoptosis in
cells with HER2 overexpression via a HER3, phosphatidylinositol 3V-
kinase–AKT–dependent pathway. Cancer Res 62 (11), 3132–3137.
[53] Bianco C, Tortora G, Bianco R, Caputo R, Veneziani BM, Damiano V,
Troiani T, Fontanini G, Raben D, Pepe S, et al. (2002). Enhancement of
antitumor activity of ionizing radiation by combined treatment with the
selective epidermal growth factor receptor – tyrosine kinase inhibitor
ZD1839 (Iressa). Clin Cancer Res 8 (10), 3250–3258.
[54] Luo Y, Shoemaker AR, Liu X, Woods KW, Thomas SA, de Jong R, Han
EK, Li T, Stoll VS, Powlas JA, et al. (2005). Potent and selective inhib-
itors of Akt kinases slow the progression of tumors in vivo. Mol Cancer
Ther 4 (6), 977–986.
[55] Liu X, Shi Y, Han EK, Chen Z, Rosenberg SH, Giranda VL, Luo Y, and
Ng SC (2001). Downregulation of Akt1 inhibits anchorage-independent
cell growth and induces apoptosis in cancer cells. Neoplasia (New
York) 3 (4), 278–286.
[56] Hu Y, Qiao L, Wang S, Rong SB, Meuillet EJ, Berggren M, Gallegos A,
Powis G, and Kozikowski AP (2000). 3-(Hydroxymethyl) – bearing
phosphatidylinositol ether lipid analogues and carbonate surrogates
block PI3-K, Akt, and cancer cell growth. J Med Chem 43 (16),
3045–3051.
[57] Meuillet Emmanuelle J, Mahadevan D, Vankayalapati H, Berggren M,
Williams R, Coon A, Kozikowski Alan P, and Powis G (2003). Specific
inhibition of the Akt1 pleckstrin homology domain by D-3-deoxy-
phosphatidyl-myo-inositol analogues.Mol Cancer Ther 2 (4), 389–399.
[58] Howells LM, Gallacher HB, Houghton CE, Manson MM, and Hudson EA
(2002). Indole-3-carbinol inhibits protein kinase B/Akt and induces
apoptosis in the human breast tumor cell line MDA MB468 but not in
the nontumorigenic HBL100 line. Mol Cancer Ther 1 (13), 1161–1172.
[59] Martelli AM, Tazzari PL, Tabellini G, Bortul R, Billi AM,Manzoli L, Ruggeri
A, Conte R, and Cocco L (2003). A new selective AKT pharmacological
inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-
trans-retinoic acid, and ionizing radiation of human leukemia cells. Leu-
kemia 17 (9), 1794–1805.
[60] Yang L, Dan Han C, Sun M, Liu Q, Feldman-Richard I, Hamilton Andrew
D, Polokoff M, Nicosia Santo V, Herlyn M, Sebti Said M, et al. (2004).
Akt/protein kinase B signaling inhibitor-2, a selective small molecule
inhibitor of Akt signaling with antitumor activity in cancer cells over-
expressing Akt. Cancer Res 64 (13), 4394–4399.
[61] DeFeo-Jones D, Barnett SF, Fu S, Hancock PJ, Haskell KM, Leander
KR, McAvoy E, Robinson RG, Duggan ME, Lindsley CW, et al.
(2005). Tumor cell sensitization to apoptotic stimuli by selective inhibi-
tion of specific Akt/PKB family members. Mol Cancer Ther 4 (2),
271–279.
[62] Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB, and McConkey
DJ (2002). Inhibition of the phosphatidylinositol 3V-kinase–AKT path-
way induces apoptosis in pancreatic carcinoma cells in vitro and in vivo.
Mol Cancer Ther 1 (12), 989–997.
1000 Akt Inhibitors Sensitize Tumors to Chemotherapy Shi et al.
Neoplasia . Vol. 7, No. 11, 2005
